Clinical Trial Update: The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating multiple-dose JS004 in head and neck cancers, assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• JS004 (JS004)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED